Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of a progressive, sub-symptom threshold aerobic exercise program on adults with persistent symptoms after mild traumatic brain injury mTBI, also known as post-concussion syndrome PCS. This condition affects 20% to 30% of individuals following mTBI and can cause ongoing symptoms including exercise intolerance and autonomic nervous system ANS dysfunction. The study aims to better understand the neurobiological factors involved in PCS and to develop targeted interventions for those with lasting symptoms. Participants with exercise intolerance will be randomly assigned to either an intervention group or a control group. The intervention group will receive a personalized aerobic exercise program to be done approximately 3 to 5 times per week for 12 weeks, exercising at 80-90% of their maximum heart rate threshold assessed by the Buffalo Concussion Treadmill Test BCTT. They will have one guided session weekly for the first three weeks and will perform other sessions independently, using various activities like walking, jogging, or swimming, monitored by heart rate and perceived exertion scales. The control group will receive standard outpatient rehabilitation from a multidisciplinary team. During the study, participants will undergo medical examinations and assessments including BCTT, Arterial Spin Labeling MRI, and the Cold Pressor Test to evaluate ANS function and symptom burden. Symptom severity will be measured using the Rivermead Post-concussion Symptom Questionnaire and other patient-reported outcomes. Exercise adherence will be tracked through diaries and weekly follow-ups. The main outcome is symptom improvement after 12 weeks, with safety and quality of life also monitored. The study lasts 12 weeks with assessments at baseline and after the intervention.
Actively Recruiting
Researchers are evaluating the effects of Medisinstart, a pharmacy counseling service, among adults starting new medication for type 2 diabetes. This randomized controlled trial aims to understand how Medisinstart influences medication use and patient adherence, which is important for improving health outcomes and benefits for patients and society. The study compares Medisinstart with usual prescription dispensing without additional counseling. Participants in the intervention group receive two follow-up consultations with a pharmacist as part of Medisinstart, while the control group receives standard prescription dispensing. The study collects data through blood tests measuring HbA1c, an established indicator of blood sugar control, and questionnaires assessing medication adherence, beliefs about medicines, diabetes self-management, and treatment satisfaction at baseline, 6 months, and 12 months after starting the new medication. During the study, participants provide blood samples for HbA1c analysis and complete questionnaires to report on their medication use and diabetes management. Researchers monitor medication-related problems and patient beliefs about medicines during the follow-up consultations. The main outcomes measured include HbA1c levels at baseline, 6 months, and 12 months, with additional assessments of adherence and treatment satisfaction over the same periods. The total study duration for each participant spans one year after starting the new diabetes medication.